While TLR-3 antagonists may prove to be of use for treating SARS-CoV-2, this might only be during a narrow window early in the course of infection because, based on the findings reported here, these agents would mainly be effective during active viremia before senescent cell abundance has been increased. This evidence concerns the gene TLR3 and infection.